Telix Pharmaceuticals Limited reported $477 million in revenue for the first half of 2026 [3].
The results signal strong commercial momentum for the company as it scales its late-stage pipeline and expands its market presence across the U.S. and Australia.
The company, which is listed on both the NASDAQ and the Australian Securities Exchange, reported a 146% jump in adjusted EBITDA [4]. This financial growth accompanies double-digit revenue growth as the firm executes its commercial strategy [5].
Looking toward the end of the year, Telix provided revenue guidance for the full year of 2026 between $950 million and $970 million [1]. This projection suggests the company expects to maintain its current pace of growth through the second half of the year.
While revenue targets remain steady, the company increased its guidance for research and development spending. Telix now expects R&D costs for 2026 to range between $230 million and $270 million [2].
The financial period ended June 30, 2026 [6]. The updated guidance reflects the company's commitment to its late-stage pipeline—a move that increases short-term spending to potentially secure long-term growth.
“Telix Pharmaceuticals reported $477 million in revenue for the first half of 2026.”
The simultaneous increase in R&D spending and the surge in EBITDA indicates that Telix is in a high-growth phase where it can afford to aggressively fund new drug development using its current commercial success. By raising the R&D ceiling while maintaining near-billion-dollar revenue guidance, the company is betting that immediate investment in its pipeline will sustain its double-digit growth trajectory beyond 2026.
